Funding Announcements

"HelloSelf is about giving everyone access to the personalised psychological advice they need. We want to help make Every Self Better. I’m delighted that Octopus has joined the mission. There are over 1.2Bn people who are underserved globally so with this investment and the trust of our network we can accelerate HelloSelf’s impact across the UK and beyond."

"We’re pleased to have backed CanSense during this investment round with equity support. Their testing technology shows huge potential, with benefits for NHS backlogs if adopted widely, and we’re glad to support the work of this company as it brings its expertise to Wales’ increasingly strong med-tech sector."

"80% of CVD-related deaths could be avoided with updated screening practices, like in cancer, where liquid biopsy is already being used to detect the disease earlier and save lives,"

"This is the most comprehensive validation of our platform thus far. While identifying antibodies to GPCRs has traditionally been a complex and time-intensive process requiring expensive specialist technology and training, we have demonstrated that Antiverse’s drug discovery platform can achieve this in a fraction of the time and cost. GPCRs are commercially interesting targets associated with various indications, and these antibodies offer a path to first in vivo results and can potentially be our first assets. I would like to thank our investors, this funding will enable us to continue to develop these assets in-house with our academic collaborators."